What is the appropriate management for sudden back pain after a Kisunla (donanemab) infusion?

Management of Sudden Back Pain After Kisunla Infusion

Immediately stop or slow the infusion and provide symptomatic treatment with analgesics; this represents an infusion-related reaction that can be managed by reducing infusion rate and considering premedication for subsequent doses.

Understanding the Clinical Context

Sudden back pain during or after Kisunla (donanemab) infusion is an infusion-related reaction (IRR), a recognized adverse event occurring in 9-16% of patients treated with this medication 1. While the FDA label for Kisunla does not specifically list back pain as a common IRR symptom, the general principles for managing monoclonal antibody infusion reactions apply, and back pain has been documented as an IRR with other immunotherapies 2.

Immediate Management Algorithm

During Active Symptoms:

1. Stop or significantly slow the infusion immediately 1

   • Most IRRs with Kisunla occur during infusion or within 30 minutes of completion
   • However, reactions can occur hours after infusion

2. Provide symptomatic treatment:

   • Administer analgesics (acetaminophen or NSAIDs if no contraindications)
   • Monitor vital signs closely
   • Assess for other IRR symptoms: chills, nausea, flushing, dyspnea, sweating, blood pressure changes, headache, or chest pain 1

3. Clinical assessment for severity grading:

   • Mild symptoms (Grade 1-2): Back pain without systemic symptoms or hemodynamic instability
   • Moderate to severe (Grade 3-4): Back pain with significant systemic symptoms, respiratory compromise, or cardiovascular instability

Severity-Based Management

Grade 1-2 (Mild to Moderate):

• Slow the infusion rate rather than stopping completely 2
• Provide symptomatic analgesia
• Once symptoms resolve, resume infusion at half the previous rate and titrate to tolerance
• Continue monitoring for 30-60 minutes post-infusion

Grade 3-4 (Severe):

• Permanently discontinue the infusion 1
• Aggressive symptomatic treatment
• Consider hospitalization if symptoms are severe or persistent
• Evaluate for other serious complications

Critical Differential Diagnosis

Rule out ARIA (Amyloid-Related Imaging Abnormalities) - the most serious complication of Kisunla:

• While back pain alone is not typical for ARIA, assess for neurological symptoms: headache, confusion, visual changes, seizures, or focal deficits 1
• ARIA occurs most commonly in the first 24 weeks of treatment (70% of IRRs occur within first 4 infusions) 1
• If any neurological symptoms are present, obtain urgent brain MRI

Prevention for Future Infusions

For patients who experienced back pain as an IRR:

1. Premedication before subsequent doses 1:

   • Antihistamine (e.g., diphenhydramine 25-50 mg)
   • Acetaminophen 650-1000 mg
   • Consider corticosteroid (e.g., methylprednisolone) for recurrent reactions

2. Modify infusion parameters:

   • Reduce infusion rate for subsequent administrations
   • Extend infusion time beyond the standard 30 minutes
   • Evidence from PD-1 inhibitor studies suggests that reducing drug concentration or infusion rate decreases IRR risk 3

3. Enhanced monitoring:

   • Closer observation during first 4 infusions when IRRs are most common
   • Extended post-infusion monitoring period (at least 60 minutes)

Important Clinical Caveats

• Do not confuse with ARIA: Back pain as an isolated symptom is more consistent with IRR than ARIA, which typically presents with neurological symptoms 1
• Timing matters: IRRs typically occur during or within 30 minutes of infusion, though delayed reactions can occur 1
• Recurrence risk: 70% of IRRs occur within the first 4 infusions; risk decreases with subsequent doses 1
• Documentation: Ensure patient carries information about receiving Kisunla, as ARIA symptoms can mimic stroke 1

Decision Point for Continuation

Can the patient continue Kisunla after experiencing back pain?

• Yes, if: Symptoms were mild-moderate, resolved with slowing infusion, and no neurological symptoms developed
• Consider discontinuation if: Severe reaction (Grade 3-4), recurrent reactions despite premedication, or any concern for ARIA
• Mandatory discontinuation if: Hypersensitivity reaction (anaphylaxis, angioedema) develops 1

The key distinction is that isolated back pain during infusion, without systemic or neurological symptoms, represents a manageable IRR rather than a contraindication to continued therapy, provided appropriate modifications are implemented.